Posted On: 06/03/2013 3:23:41 PM
Post# of 72446
Email from Leo live at ASCO!
first the question:
I am wondering if how the cohort participants' tumors and cancer are responding to Kevetrin treatment is shared in a PR or website posting during this phase one trial. Are those doing the testing seeing encouraging responses? What ongoing results can be shared with us the investor?
Thanks, xxx
The answer:
Quote:
Hi
As you can see from the poster we are still at an escalating stage and have not yet reached the dose we believe is needed for disease regression. I know the hot stock today is Clovis. They are very specific as to cancer type in their phase 1 trial and have patients who are not terminal. Clovis is doing part of the study in Europe. It is important to note this and then you will understand that we are quite pleased with the results to date and expect the next few cohorts to give a clear answer to your question. On another note I have viewed other posters of phase 1 trials. Comparatively I am very happy with our progression. Others I noticed had to go actually backwards to regroup or file amendments with changes to dosage.
At ASCO
Best
Leo Ehrlich
first the question:
I am wondering if how the cohort participants' tumors and cancer are responding to Kevetrin treatment is shared in a PR or website posting during this phase one trial. Are those doing the testing seeing encouraging responses? What ongoing results can be shared with us the investor?
Thanks, xxx
The answer:
Quote:
Hi
As you can see from the poster we are still at an escalating stage and have not yet reached the dose we believe is needed for disease regression. I know the hot stock today is Clovis. They are very specific as to cancer type in their phase 1 trial and have patients who are not terminal. Clovis is doing part of the study in Europe. It is important to note this and then you will understand that we are quite pleased with the results to date and expect the next few cohorts to give a clear answer to your question. On another note I have viewed other posters of phase 1 trials. Comparatively I am very happy with our progression. Others I noticed had to go actually backwards to regroup or file amendments with changes to dosage.
At ASCO
Best
Leo Ehrlich
(0)
(0)
